Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature
Journal article published in 2017 by
Bo Wang 
,
Laura Abbott,
Kate Childs,
Chris Taylor,
Kosh Agarwal ,
Ian Cormack,
Rosa Miquel,
Abid Suddle
,
Laura Abbott,
Kate Childs,
Chris Taylor,
Kosh Agarwal ,
Ian Cormack,
Rosa Miquel,
Abid Suddle
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
A patient with human immunodeficiency virus-1 infection presented with sub-acute liver failure, temporally related to commencement of an antiretroviral therapy regimen containing dolutegravir (Triumeq). The patient was not a carrier of HLA-B5701, and abacavir hypersensitivity was unlikely. We believe this is the first report of severe dolutegravir-related hepatotoxicity resulting in sub-acute liver failure and transplantation and highlights a potential need for closer monitoring after drug initiation.